BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 28910952)

  • 1. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
    Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W
    Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952
    [No Abstract]   [Full Text] [Related]  

  • 2. Selective application of neuroendocrine markers in the diagnosis and treatment of small cell lung cancer.
    Du J; Li Y; Wang L; Zhou Y; Shen Y; Xu F; Chen Y
    Clin Chim Acta; 2020 Oct; 509():295-303. PubMed ID: 32592711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC).
    Shibayama T; Ueoka H; Nishii K; Kiura K; Tabata M; Miyatake K; Kitajima T; Harada M
    Lung Cancer; 2001 Apr; 32(1):61-9. PubMed ID: 11282430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
    Lamy PJ; Grenier J; Kramar A; Pujol JL
    Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
    Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
    Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pro-gastrin-releasing peptide and neuron-specific enolase: useful predictors of response to chemotherapy and survival in patients with small cell lung cancer.
    Huang Z; Xu D; Zhang F; Ying Y; Song L
    Clin Transl Oncol; 2016 Oct; 18(10):1019-25. PubMed ID: 26886220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic and prognostic value of ProGRP in lung cancer.
    Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
    Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China.
    Wu XY; Hu YB; Li HJ; Wan B; Zhang CX; Zhang B; Hu H; Zhang Q; Lv TF; Zhan P; Song Y
    J Cell Mol Med; 2018 Sep; 22(9):4328-4334. PubMed ID: 29989303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme-linked immunosorbent assay of pro-gastrin-releasing peptide for small cell lung cancer patients in comparison with neuron-specific enolase measurement.
    Yamaguchi K; Aoyagi K; Urakami K; Fukutani T; Maki N; Yamamoto S; Otsubo K; Miyake Y; Kodama T
    Jpn J Cancer Res; 1995 Jul; 86(7):698-705. PubMed ID: 7559089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Utility of NSE, ProGRP and LDH in Diagnosis and Treatment
in Patients with Small Cell Lung Cancer].
    Peng Y; Wang Y; Li J; Hao X; Hu X
    Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):590-4. PubMed ID: 27666548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pro-gastrin-releasing peptide (31-98) as a tumour marker of small-cell lung cancer: comparative evaluation with neuron-specific enolase.
    Takada M; Kusunoki Y; Masuda N; Matui K; Yana T; Ushijima S; Iida K; Tamura K; Komiya T; Kawase I; Kikui N; Morino H; Fukuoka M
    Br J Cancer; 1996 May; 73(10):1227-32. PubMed ID: 8630283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer.
    Bi H; Yin L; Fang W; Song S; Wu S; Shen J
    Lab Med; 2023 Jul; 54(4):372-379. PubMed ID: 36282321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the diagnostic and prognostic value of serum TuM2-PK, NSE, and ProGRP in small cell lung cancer.
    Li L; Zhang Q; Wang Y; Xu C
    J Clin Lab Anal; 2023 Apr; 37(7):e24865. PubMed ID: 37088873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations.
    Trulson I; Klawonn F; von Pawel J; Holdenrieder S
    Tumour Biol; 2024; 46(s1):S81-S98. PubMed ID: 38277317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
    Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
    Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
    Nisman B; Heching N; Biran H; Barak V; Peretz T
    Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnostic value of ProGRP and NSE for small cell lung cancer: a meta-analysis].
    WANG J; GAO J; HE J
    Zhongguo Fei Ai Za Zhi; 2010 Dec; 13(12):1094-100. PubMed ID: 21159242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of tumour and inflammatory markers in lung cancer.
    Oremek GM; Sauer-Eppel H; Bruzdziak TH
    Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
    Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
    Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.